For advocates, social science is an important component of effective cure research, one that is often undervalued.
A recently published study shows positive early results for a once-weekly HIV antiretroviral in pill form that slowly releases the medications, but many more steps are needed to prove it can work in humans.
There is a great deal of interest in exploring the potential of gene therapy to cure HIV and multiple gene therapy strategies are under investigation.
The death toll from HIV/AIDS continues to decline, but more than 36 million people are still living with HIV. A researcher explains why the work for a cure is painstaking.
Other Names: 4'-Ed4T, 4'-ethynyl-d4T, 4'-ethynylstavudine, BMS-986001, OBP-601, festinavir Drug Class: Nucleoside Reverse Transcriptase Inhibitors Molecular Formula: C12 H12 N2 O4 Registry Number: 634907-30-5 (CAS) Chemical Name: 1-[(2R,5R)-5-ethyny...
In the search for a cure, multiple clinical trials are investigating whether immune-based approaches can deliver the "kill" in "kick and kill."
Virally suppressed people who swapped an efavirenz regimen for one based on an integrase inhibitor gained significantly more weight over 18 months than those who stayed with efavirenz or switched to a protease inhibitor.
A major focus of HIV cure research is on reversing HIV latency -- essentially switching on the latent virus's DNA machinery so that it starts making proteins.
There are a variety of technologies available to accurately quantify the latent HIV reservoir, but each has pros and cons.
As the research effort to develop a safe, effective, broadly accessible HIV cure expands, the issue of how to measure success remains central.